Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: a review on the basis of clinical trials

Review and cost analysis of chemotherapy-induced myelosuppression events in relapsed small cell lung cancer (SCLC) patients.

Download PDF Outside URL
Skip to content